Four US Democratic politicians
have been pushing for a new bill to
reduce the patent period on new
biologic medicines from 12 to seven
years, following on from Barack
Obama’s attempts since 2010 to
reduce the exclusivity period.
Under the US Patient Protection
and Affordable Care Act’s Biologics
Price Competition and Innovation
Act however, the US Food and Drug
Administration still cannot approve
any biosimilars within the 12 year
exclusivity period.
The Democratic push has failed
again on this occasion with
international free trade agreements
creating complicated sticking
points, according to the Regulatory
Affairs Professional Society (RAPS).The above article was sent to subscribers in Pharmacy Daily's issue from 24 Jun 16 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 24 Jun 16
THE stark health inequalities between Australians living in regional and metro areas have been highlighted in a new report from The Royal Flying Doctor Service (RFDS).
AN “AI explosion” is sweeping Australia’s healthcare sector, signalling the arrival of an “extraordinary era of medicine”, according to a new report from CSIRO.
THE Australian and New Zealand College of Advanced Pharmacy (ANZCAP) has celebrated the 1,000th pharmacist to complete its pharmacy recognition program (PD 24 Nov 2023).
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.